Eurand Appoints Chief Scientific Officer
November 16 2005 - 2:00AM
PR Newswire (US)
MILAN, Italy, Nov. 16 /PRNewswire/ -- Eurand, a specialty
pharmaceutical company, today announced the appointment of Dr.
Costantinos Efthymiopoulos to the position of Chief Scientific
Officer. In this position, Dr. Efthymiopoulos will be responsible
for global Research and Development, Clinical Development and
Regulatory Affairs. The appointment will take effect on January
9th, 2006. "We are delighted to have attracted a manager of
Costantinos's calibre to Eurand," commented Gearoid Faherty, Chief
Executive Officer of Eurand. "With more than 22 years of experience
in the pharmaceutical and biotechnology industry, we are confident
that Costantinos will make a significant contribution to the
development of Eurand." Prior to joining Eurand, Dr. Efthymiopoulos
worked for Serono, (SWX:SEO) ( NYSE: SRA) based in Geneva,
Switzerland, most recently, as Corporate VP, Head of the
Dermatology Therapeutic Area. In this position he led the creation
of a new therapeutic area for Serono, including the worldwide
launch of Raptiva(R), for the treatment of psoriasis. Dr.
Efthymiopoulos began his career in research at the Laboratory of
Medicinal Chemistry at the University of Strasbourg. Subsequently
he joined Farmitalia Carlo Erba in Milan where he was appointed
Head of the Pharmacokinetic Analysis Group. He then moved to
GlaxoWellcome in London, where he held various scientific and
managerial positions in Clinical Pharmacology. Dr. Efthymiopoulos
has a Bachelor of Pharmacy degree from the University of Athens, an
M.Sc. in Industrial Pharmacy and an M.Sc. in Molecular and Cellular
Pharmacology and Medicinal Chemistry as well as a Ph.D. in
Pharmacology (Pharmacokinetics) from the University of Strasbourg.
He also holds an M.B.A. from the London Business School. Dr.
Efthymiopoulos is author/co-author of more than 60 scientific
publications and of two patents and has held visiting Professor
appointments at the University of Strasbourg and at the University
of Padova. About Eurand Eurand is a privately held specialty
pharmaceutical company that develops enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug delivery
technologies. The Company specializes in four areas:
bioavailability enhancement of poorly soluble drugs, customized
release, taste masking/fast-dissolving formulations, and drug
targeting. Eurand has had three products approved by the FDA since
2000 and is currently developing a pipeline of products based on
its proprietary drug delivery technology. The company also works
with many of the world's leading pharmaceutical and biotechnology
companies to develop enhanced forms of their existing products and
development compounds. Eurand is a global company with more than
500 employees and annual revenue of more than $100 million. Eurand
is based in Milan, Italy, with research, development and
manufacturing facilities throughout the world, including sites in
Milan, Italy; Dayton, Ohio (US) and Paris, France. For more
information, visit Eurand's website at http://www.eurand.com/.
DATASOURCE: Eurand CONTACT: Gearoid Faherty, CEO, Eurand, Italy:
+39-02-954281, ; or John Capodanno, Financial Dynamics,
+1-212-850-5705 Web site: http://www.eurand.com/
Copyright